Literature DB >> 15383200

The prevalence of anemia in patients with chronic kidney disease.

William McClellan1, Stephen L Aronoff, W Kline Bolton, Sally Hood, Daniel L Lorber, K Linda Tang, Thomas F Tse, Brian Wasserman, Marc Leiserowitz.   

Abstract

OBJECTIVE: Anemia is a complication of chronic kidney disease and may contribute to adverse clinical outcomes. Early identification and treatment of anemia may improve cardiovascular morbidity and mortality. No large-scale population data are available specifically for patients with chronic kidney disease regarding prevalence of anemia, subpopulations at risk, and relationships between anemia and kidney function. This study was undertaken to address these questions in patients with chronic kidney disease, and investigate the relationship between anemia and glomerular filtration rate. RESEARCH DESIGN AND METHODS: Large-scale, cross-sectional, US multicenter survey; 5222 patients (mean age, 68.2 years; 46.6% male); 237 physician practices. Eligible patients: > or = 18 years of age; serum creatinine: 1.5 mg/dL-6.0 mg/dL (females), 2.0 mg/dL-6.0 mg/dL (males). MAIN OUTCOME MEASURES: Primary study end point: prevalence and severity of anemia (hemoglobin < or = 12 g/dL). Data further stratified by hemoglobin (< or = 12 g/dL, < or = 10 g/dL).
RESULTS: Primary etiologies of chronic kidney disease (5222 evaluable patients): diabetes (49.5%); hypertension (33.0%). Glomerular filtration rate: < 60 mL/min/1.73 m2 for 97.7% of evaluable patients. Mean +/- SD serum creatinine level: 2.2 mg/dL +/- 0.9 mg/dL; 2.5 mg/dL +/- 1.0 mg/dL for males, 2.0 mg/dL +/- 0.8 mg/dL for females. Mean +/- SD hemoglobin: 12.2 g/dL +/- 1.6 g/dL (47.7% had hemoglobin < or = 12 g/dL; 8.9% had hemoglobin < or = 10 g/dL). Prevalence of anemia was strongly associated with declining glomerular filtration rate. Percentage of patients with hemoglobin < or = 12 g/dL increased from 26.7% to 75.5% when glomerular filtration rate decreased from > or = 60 mL/min/1.73 m2 to < 15 mL/min/1.73 m2. Prevalence of hemoglobin < or = 10 g/dL increased substantially from 5.2% to 27.2% when glomerular filtration rate diminished from > or = 60 mL/min/1.73 m2 to < 15 mL/min/1.73 m2. After controlling for other patient characteristics associated with increased prevalence of anemia, the prevalence odds ratio for hemoglobin < or = 10 g/dL was 0.54 (0.49-0.60) and for hemoglobin < or = 12 g/dL was 0.68 (0.65-0.72), with each 10-mL/min/1.73 m2 increase in glomerular filtration rate. Predictors of anemia: diabetes, female sex, and race/ethnicity.
CONCLUSIONS: Anemia was present in 47.7% of 5222 predialysis patients with chronic kidney disease. Prevalence of anemia increased as kidney function decreased. Certain subgroups are at increased risk for anemia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15383200     DOI: 10.1185/030079904X2763

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  113 in total

1.  Should erythropoiesis-stimulating agents be used in predialysis patients?

Authors:  Rene Breault
Journal:  Can J Hosp Pharm       Date:  2011-03

2.  Modeling red blood cell survival data.

Authors:  Julia Korell; Frederiek E Vos; Carolyn V Coulter; John B Schollum; Robert J Walker; Stephen B Duffull
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-10-14       Impact factor: 2.745

Review 3.  Cardiovascular risk factors following renal transplant.

Authors:  Jill Neale; Alice C Smith
Journal:  World J Transplant       Date:  2015-12-24

4.  Anemia in patients on chronic hemodialysis in Cameroon: prevalence, characteristics and management in low resources setting.

Authors:  Francois Folefack Kaze; Andre-Pascal Kengne; Alex Tatang Mambap; Marie-Patrice Halle; Dora Mbanya; Gloria Ashuntantang
Journal:  Afr Health Sci       Date:  2015-03       Impact factor: 0.927

5.  Renal denervation in moderate to severe CKD.

Authors:  Dagmara Hering; Felix Mahfoud; Antony S Walton; Henry Krum; Gavin W Lambert; Elisabeth A Lambert; Paul A Sobotka; Michael Böhm; Bodo Cremers; Murray D Esler; Markus P Schlaich
Journal:  J Am Soc Nephrol       Date:  2012-05-17       Impact factor: 10.121

6.  Safety of a Restrictive versus Liberal Approach to Red Blood Cell Transfusion on the Outcome of AKI in Patients Undergoing Cardiac Surgery: A Randomized Clinical Trial.

Authors:  Amit X Garg; Neal Badner; Sean M Bagshaw; Meaghan S Cuerden; Dean A Fergusson; Alexander J Gregory; Judith Hall; Gregory M T Hare; Boris Khanykin; Shay McGuinness; Chirag R Parikh; Pavel S Roshanov; Nadine Shehata; Jessica M Sontrop; Summer Syed; George I Tagarakis; Kevin E Thorpe; Subodh Verma; Ron Wald; Richard P Whitlock; C David Mazer
Journal:  J Am Soc Nephrol       Date:  2019-06-20       Impact factor: 10.121

7.  Darbepoetin alfa for the treatment of anemia in pediatric patients with chronic kidney disease.

Authors:  Bradley A Warady; Mazen Y Arar; Gary Lerner; Arline M Nakanishi; Catherine Stehman-Breen
Journal:  Pediatr Nephrol       Date:  2006-05-25       Impact factor: 3.714

Review 8.  Anaemia in diabetes: Is there a rationale to TREAT?

Authors:  M C Thomas; M E Cooper; K Rossing; H H Parving
Journal:  Diabetologia       Date:  2006-04-04       Impact factor: 10.122

Review 9.  Controversial issues in CKD clinical practice: position statement of the CKD-treatment working group of the Italian Society of Nephrology.

Authors:  Vincenzo Bellizzi; Giuseppe Conte; Silvio Borrelli; Adamasco Cupisti; Luca De Nicola; Biagio R Di Iorio; Gianfranca Cabiddu; Marcora Mandreoli; Ernesto Paoletti; Giorgina B Piccoli; Giuseppe Quintaliani; Maura Ravera; Domenico Santoro; Serena Torraca; Roberto Minutolo
Journal:  J Nephrol       Date:  2016-08-27       Impact factor: 3.902

10.  C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial.

Authors:  Iain C Macdougall; Rowan Walker; Robert Provenzano; Fernando de Alvaro; Harold R Locay; Paul C Nader; Francesco Locatelli; Frank C Dougherty; Ulrich Beyer
Journal:  Clin J Am Soc Nephrol       Date:  2008-02-20       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.